T LYMPHOCYTE, T CELL RECEPTOR, CELLULAR IMMUNITY, IMMUNOTHERAPY
T LYMPHOCYTE, T CELL RECEPTOR, CELLULAR IMMUNITY, IMMUNOTHERAPY
批准号:
7958182
负责人:
MARY S LANIER
金额:
$5.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2010-04-30
关键词:
AcuteAdoptive TransferAffectAntigensCell SurvivalCellsCellular ImmunityChronicChronic DiseaseComputer Retrieval of Information on Scientific Projects DatabaseExposure toFundingGrantHIV InfectionsImmuneImmune responseImmunotherapyInfectionInstitutionKineticsLeadLewis Lung CarcinomaLymphocytic choriomeningitis virusModelingNeoplasm TransplantationPopulationPrimatesReportingResearchResearch PersonnelResourcesSourceT-Cell ReceptorT-LymphocyteTherapeuticTimeTransgenic ModelUnited States National Institutes of HealthWorkcytokinetherapeutic developmenttumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The purpose of this study is to examine how ongoing acute and chronic infections and exposure to tumors affect na¿ve bystander T cell populations.
During the reporting period, we continued our studies analyzing the status, kinetics, and stability of na¿ve T cells during acute and chronic infections and to determine how chronic antigen exposure during persistent infections or persisting tumors has on the ability of bystander na¿ve T cells to mount immune responses. We also worked to determine the effect of introducing therapeutic cytokines during a chronic infection or tumor model has on bystander na¿ve T cells.
Using a TCR transgenic model we exposed, by adoptive transfer, OVA TCR na¿ve T cells to acute LCMV infection or Lewis Lung Carcinoma tumor transplant model, recovered OVA na¿ve cells then determine their ability to respond to OVA infection.
We will continue to work to develop clues in the timing of therapies that will lead to therapeutic developments for targeting na¿ve T cell viability during chronic diseases and immune suppression, for example HIV infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T LYMPHOCYTE, T CELL RECEPTOR, CELLULAR IMMUNITY, IMMUNOTHERAPY
-
批准号:8172367
-
项目类别:
-
资助金额:$5.48万
-
财政年份:2010
-
负责人:MARY S LANIER
-
依托单位:
T LYMPHOCYTE, T CELL RECEPTOR, CELLULAR IMMUNITY, IMMUNOTHERAPY
-
批准号:7715767
-
项目类别:
-
资助金额:$3.56万
-
财政年份:2008
-
负责人:MARY S LANIER
-
依托单位:
T LYMPHOCYTE, T CELL RECEPTOR, CELLULAR IMMUNITY, IMMUNOTHERAPY
-
批准号:7562627
-
项目类别:
-
资助金额:$6.55万
-
财政年份:2007
-
负责人:MARY S LANIER
-
依托单位:
T LYMPHOCYTE, T CELL RECEPTOR, CELLULAR IMMUNITY, IMMUNOTHERAPY
-
批准号:7349296
-
项目类别:
-
资助金额:$5.97万
-
财政年份:2006
-
负责人:MARY S LANIER
-
依托单位:
海外基金